AIM ImmunoTech Inc. (AIM)
USD 0.2
(-6.89%)
USD 0.2
(-6.89%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 32.07 Million USD | 59.87% |
| 2022 | 20.06 Million USD | 22.76% |
| 2021 | 16.34 Million USD | 13.71% |
| 2020 | 14.37 Million USD | 22.96% |
| 2019 | 11.69 Million USD | 6.48% |
| 2018 | 10.97 Million USD | 2.9% |
| 2017 | 10.67 Million USD | -16.56% |
| 2016 | 12.78 Million USD | -15.79% |
| 2015 | 15.18 Million USD | -15.85% |
| 2014 | 18.04 Million USD | 12.2% |
| 2013 | 16.08 Million USD | -13.36% |
| 2012 | 18.56 Million USD | 38.4% |
| 2011 | 13.41 Million USD | -11.65% |
| 2010 | 15.18 Million USD | 18.69% |
| 2009 | 12.79 Million USD | 4.18% |
| 2008 | 12.27 Million USD | -36.77% |
| 2007 | 19.41 Million USD | 5.81% |
| 2006 | 18.35 Million USD | 77.64% |
| 2005 | 10.33 Million USD | 3.25% |
| 2004 | 10 Million USD | 35.09% |
| 2003 | 7.4 Million USD | 6.41% |
| 2002 | 6.96 Million USD | -24.27% |
| 2001 | 9.19 Million USD | -10.91% |
| 2000 | 10.31 Million USD | -2.66% |
| 1999 | 10.6 Million USD | 34.18% |
| 1998 | 7.9 Million USD | 14.49% |
| 1997 | 6.9 Million USD | 38.0% |
| 1996 | 5 Million USD | 16.28% |
| 1995 | 4.3 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.7 Million USD | -59.18% |
| 2024 Q2 | 3.67 Million USD | -34.55% |
| 2023 Q4 | 13.98 Million USD | 71.11% |
| 2023 Q2 | 5.5 Million USD | 26.68% |
| 2023 Q3 | 8.17 Million USD | 48.52% |
| 2023 Q1 | 4.34 Million USD | -22.59% |
| 2023 FY | 31.82 Million USD | 58.61% |
| 2022 Q1 | 3.1 Million USD | -43.9% |
| 2022 FY | 20.06 Million USD | 22.76% |
| 2022 Q4 | 5.61 Million USD | -14.22% |
| 2022 Q3 | 6.54 Million USD | 40.51% |
| 2022 Q2 | 4.65 Million USD | 49.81% |
| 2021 Q3 | 3.8 Million USD | 9.91% |
| 2021 FY | 16.34 Million USD | 13.71% |
| 2021 Q4 | 5.54 Million USD | 45.6% |
| 2021 Q1 | 3.53 Million USD | -27.23% |
| 2021 Q2 | 3.46 Million USD | -2.09% |
| 2020 Q2 | 3.18 Million USD | 0.44% |
| 2020 Q4 | 4.85 Million USD | 52.46% |
| 2020 Q3 | 3.18 Million USD | 0.22% |
| 2020 FY | 14.37 Million USD | 22.96% |
| 2020 Q1 | 3.16 Million USD | 8.39% |
| 2019 Q2 | 3.03 Million USD | 12.73% |
| 2019 Q3 | 3.03 Million USD | -0.07% |
| 2019 FY | 11.69 Million USD | 6.48% |
| 2019 Q4 | 2.92 Million USD | -3.79% |
| 2019 Q1 | 2.69 Million USD | 2.9% |
| 2018 Q3 | 2.86 Million USD | -6.7% |
| 2018 Q1 | 2.41 Million USD | -5.06% |
| 2018 Q4 | 2.61 Million USD | -8.68% |
| 2018 FY | 10.97 Million USD | 2.9% |
| 2018 Q2 | 3.07 Million USD | 27.13% |
| 2017 Q2 | 2.72 Million USD | -10.8% |
| 2017 Q4 | 2.54 Million USD | 8.71% |
| 2017 Q1 | 3.05 Million USD | -20.09% |
| 2017 FY | 10.67 Million USD | -16.56% |
| 2017 Q3 | 2.34 Million USD | -14.02% |
| 2016 FY | 12.78 Million USD | -15.79% |
| 2016 Q1 | 3.45 Million USD | 37.78% |
| 2016 Q2 | 2.53 Million USD | -26.41% |
| 2016 Q3 | 2.97 Million USD | 17.21% |
| 2016 Q4 | 3.82 Million USD | 28.46% |
| 2015 Q3 | 3.65 Million USD | -17.74% |
| 2015 Q1 | 4.58 Million USD | 7.05% |
| 2015 Q4 | 2.5 Million USD | -31.45% |
| 2015 Q2 | 4.44 Million USD | -3.18% |
| 2015 FY | 15.18 Million USD | -15.85% |
| 2014 Q1 | 4.86 Million USD | 47.78% |
| 2014 Q4 | 4.28 Million USD | 5.33% |
| 2014 FY | 18.04 Million USD | 12.2% |
| 2014 Q2 | 4.82 Million USD | -0.78% |
| 2014 Q3 | 4.06 Million USD | -15.72% |
| 2013 Q1 | 4.41 Million USD | -41.43% |
| 2013 Q4 | 3.29 Million USD | -22.41% |
| 2013 FY | 16.08 Million USD | -13.36% |
| 2013 Q3 | 4.24 Million USD | 2.61% |
| 2013 Q2 | 4.13 Million USD | -6.3% |
| 2012 Q3 | 4.01 Million USD | 15.6% |
| 2012 Q2 | 3.47 Million USD | -1.84% |
| 2012 Q1 | 3.53 Million USD | 0.85% |
| 2012 Q4 | 7.53 Million USD | 87.62% |
| 2012 FY | 18.56 Million USD | 38.4% |
| 2011 Q3 | 3.38 Million USD | 9.9% |
| 2011 Q2 | 3.08 Million USD | -10.44% |
| 2011 Q1 | 3.43 Million USD | -17.88% |
| 2011 FY | 13.41 Million USD | -11.65% |
| 2011 Q4 | 3.5 Million USD | 3.66% |
| 2010 Q2 | 3.48 Million USD | -12.18% |
| 2010 Q3 | 3.54 Million USD | 1.84% |
| 2010 Q4 | 4.18 Million USD | 18.1% |
| 2010 Q1 | 3.96 Million USD | 3.01% |
| 2010 FY | 15.18 Million USD | 18.69% |
| 2009 Q4 | 3.84 Million USD | 64.7% |
| 2009 FY | 12.79 Million USD | 4.18% |
| 2009 Q1 | 2.76 Million USD | -3.29% |
| 2009 Q2 | 3.84 Million USD | 39.22% |
| 2009 Q3 | 2.33 Million USD | -39.2% |
| 2008 FY | 12.27 Million USD | -36.77% |
| 2008 Q4 | 2.85 Million USD | -12.66% |
| 2008 Q3 | 3.26 Million USD | 10.81% |
| 2008 Q1 | 3.2 Million USD | -22.5% |
| 2008 Q2 | 2.95 Million USD | -7.93% |
| 2007 Q2 | 4.07 Million USD | -17.79% |
| 2007 Q3 | 6.24 Million USD | 53.25% |
| 2007 Q1 | 4.95 Million USD | 13.53% |
| 2007 Q4 | 4.13 Million USD | -33.83% |
| 2007 FY | 19.41 Million USD | 5.81% |
| 2006 Q3 | 3.78 Million USD | -18.96% |
| 2006 FY | 18.35 Million USD | 77.64% |
| 2006 Q2 | 4.67 Million USD | -15.37% |
| 2006 Q4 | 4.36 Million USD | 15.31% |
| 2006 Q1 | 5.52 Million USD | 71.47% |
| 2005 Q1 | 2.25 Million USD | 8.12% |
| 2005 Q4 | 3.22 Million USD | 40.47% |
| 2005 FY | 10.33 Million USD | 3.25% |
| 2005 Q2 | 2.56 Million USD | 14.09% |
| 2005 Q3 | 2.29 Million USD | -10.67% |
| 2004 FY | 10 Million USD | 35.09% |
| 2004 Q1 | 3.8 Million USD | 66.8% |
| 2004 Q2 | 1.83 Million USD | -51.84% |
| 2004 Q3 | 2.27 Million USD | 23.94% |
| 2004 Q4 | 2.08 Million USD | -8.45% |
| 2003 FY | 7.4 Million USD | 6.41% |
| 2003 Q4 | 2.28 Million USD | 20.73% |
| 2003 Q3 | 1.89 Million USD | 11.7% |
| 2003 Q1 | 1.54 Million USD | 96.93% |
| 2003 Q2 | 1.69 Million USD | 9.94% |
| 2002 Q1 | 2.12 Million USD | 21.2% |
| 2002 Q4 | 782 Thousand USD | -60.12% |
| 2002 Q3 | 1.96 Million USD | -6.49% |
| 2002 Q2 | 2.09 Million USD | -1.13% |
| 2002 FY | 6.96 Million USD | -24.27% |
| 2001 Q2 | 2.5 Million USD | -7.64% |
| 2001 Q3 | 2.26 Million USD | -9.66% |
| 2001 Q4 | 1.75 Million USD | -22.63% |
| 2001 FY | 9.19 Million USD | -10.91% |
| 2001 Q1 | 2.71 Million USD | -4.49% |
| 2000 Q3 | 2.54 Million USD | 1.2% |
| 2000 FY | 10.31 Million USD | -2.66% |
| 2000 Q2 | 2.51 Million USD | -0.52% |
| 2000 Q1 | 2.52 Million USD | 9.76% |
| 2000 Q4 | 2.83 Million USD | 11.69% |
| 1999 FY | 10.6 Million USD | 34.18% |
| 1999 Q4 | 2.3 Million USD | 0.0% |
| 1999 Q3 | 2.3 Million USD | -20.69% |
| 1999 Q2 | 2.9 Million USD | -9.38% |
| 1999 Q1 | 3.2 Million USD | 39.13% |
| 1998 Q1 | 1.8 Million USD | 5.88% |
| 1998 Q2 | 1.8 Million USD | 0.0% |
| 1998 Q3 | 2 Million USD | 11.11% |
| 1998 FY | 7.9 Million USD | 14.49% |
| 1998 Q4 | 2.3 Million USD | 15.0% |
| 1997 Q2 | 1.3 Million USD | -48.0% |
| 1997 Q3 | 1.6 Million USD | 23.08% |
| 1997 FY | 6.9 Million USD | 38.0% |
| 1997 Q4 | 1.7 Million USD | 6.25% |
| 1997 Q1 | 2.5 Million USD | 78.57% |
| 1996 Q1 | 800 Thousand USD | 120.0% |
| 1996 Q4 | 1.4 Million USD | -17.65% |
| 1996 FY | 5 Million USD | 16.28% |
| 1996 Q3 | 1.7 Million USD | 54.55% |
| 1996 Q2 | 1.1 Million USD | 37.5% |
| 1995 Q4 | -4 Million USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 FY | 4.3 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -246.094% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -175.354% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 38.317% |
| Azitra, Inc. | 8.3 Million USD | -286.346% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -258.872% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -367.425% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | -10.637% |
| CEL-SCI Corporation | 31.47 Million USD | -1.906% |
| iBio, Inc. | 16.85 Million USD | -90.26% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 2.821% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -58.931% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | -29.016% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -130.239% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -148.69% |
| NanoViricides, Inc. | 8.51 Million USD | -276.651% |
| Oragenics, Inc. | 5.45 Million USD | -488.34% |
| BiomX Inc. | 26.81 Million USD | -19.624% |
| BiomX Inc. | 26.81 Million USD | -19.624% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | -0.075% |
| Palatin Technologies, Inc. | 34.67 Million USD | 7.483% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 19.439% |